Working… Menu

Hemostatic Profile in Patients Affected by COVID-19 (EMO-COVID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04595110
Recruitment Status : Recruiting
First Posted : October 20, 2020
Last Update Posted : October 20, 2020
Information provided by (Responsible Party):
ANNA FALANGA, A.O. Ospedale Papa Giovanni XXIII

Brief Summary:

Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), has been associated with the occurrence of cardiovascular adverse events including acute myocardial injury, acute heart failure, cardiac arrhythmias, and thromboembolic disease. These complications represent an important issue in COVID-19 patients accounting for the increased morbidity and mortality of this syndrome. According to a scoping review, venous thromboembolism and stroke occurred in approximately 20% and 3% of patients, respectively, with higher frequency observed in severely ill patients admitted to intensive care units. Despite the use of pharmacological thromboprophylaxis, the thrombotic risk still remained elevated in severe COVID-19 patients, and the optimal doses and timing of anticoagulation are not yet defined. The pathogenesis of COVID-19 associated thrombosis recognizes a prominent role of endothelial damage induced by both direct viral injury and an excessive and aberrant hyper-inflammatory host immune response associated to an increase in infection-related cytokines and chemokines. The occurrence of a hypercoagulable state in COVID-19 patients associated to a profound endothelial cell activation/dysfunction can result in the pathological phenomenon of immunothrombosis.

In this study, in a prospective cohort of consecutive COVID-19 hospitalized patients, an extensive characterization of the hemostatic alterations were performed, in order to: 1) clarify mechanisms underlying the coagulopathy in these patients; 2) how and to what extent the concomitant infection with SARS-CoV-2 affect this coagulopathy; and 3) identify biomarkers potentially predictive of disease outcome (i.e. any thrombotic recurrence and death).

Condition or disease Intervention/treatment
Covid19 Thrombosis Other: Observational study

Layout table for study information
Study Type : Observational
Estimated Enrollment : 400 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Extensive Investigation of the Hemostatic Profile in a Prospective Cohort of Patients Affected by COVID-19
Actual Study Start Date : March 25, 2020
Estimated Primary Completion Date : April 25, 2021
Estimated Study Completion Date : May 10, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Clots

Intervention Details:
  • Other: Observational study
    Coagulation factors, Hypercoagulation biomarkers, Endothelial, Fibrinolysis and neutrophil activation biomarkers

Primary Outcome Measures :
  1. Incidence of mortality among enrolled COVID-19 patients [ Time Frame: up to 6 months from the date of the enrollment ]
    Identification of variables for prediction of mortality derived from review of clinical records. Samples collected from identified participants with COVID19 diagnosis will be assessed to determine thrombotic and inflammatory biomarkers able to prediction of mortality.

  2. Incidence of thrombosis among enrolled COVID patients [ Time Frame: up to 12 months from the date of the enrollment ]
    Identification of COVID-19 patients with evidence of thrombotic event derived from review of clinical records. Samples collected from identified participants with COVID19 diagnosis will be assessed to determine thrombotic and inflammatory biomarkers.

Secondary Outcome Measures :
  1. Evaluation the role of enoxaparin in the management of Covid-19-associated coagulopathy [ Time Frame: Samples collected from identified participants with COVID19 diagnosis will be assessed to determine the effect of thromboprophylaxis on thrombotic and inflammatory biomarkers ]
    up to 12 months from the date of the enrollment

Biospecimen Retention:   Samples Without DNA
Blood samples for hemostasis study are collected from all study subjects at admission. After discarding the first 2-3 mL of blood, peripheral venous blood samples were collected into 6 mL vacuum tubes (BD, Vacutainer ™, Plymouth, UK) containing 3.2% citrate (0.109 mol/L, 1:9 vol./vol.) for coagulation studies, and K3-ethylenediamine tetraacetic acid (K3-EDTA) 7.2mg for the complete blood cell count study.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The study involves the enrollment of ≥ 400 consecutive hospitalized patients diagnosed with COVID-19, aged> 18 years.

Inclusion Criteria:

  • Age> 18 years
  • Adult patients admitted with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) positivity (by real time-PCR) from nasal swab or deep respiratory specimen or with clinical signs suggestive of SARS-Cov-2
  • Patients who have signed informed consent. If there is no possibility of obtaining informed consent for the clinical picture (eg adult patients sedated and curarized for acute respiratory failure and consequent mechanical ventilation), the patient's consent will be assumed until the contrary will be manifested.

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04595110

Layout table for location information
Papa Giovanni XXIII Hospital - S.I.M.T. Recruiting
Bergamo, Italy, 24127
Contact: Anna Falanga, MD    +390352674776   
Contact: Laura Russo, BSc   
Sponsors and Collaborators
Layout table for additonal information
Responsible Party: ANNA FALANGA, Principal Investigator, A.O. Ospedale Papa Giovanni XXIII Identifier: NCT04595110    
Other Study ID Numbers: EMO-COVID-ASSTPG23
First Posted: October 20, 2020    Key Record Dates
Last Update Posted: October 20, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by ANNA FALANGA, A.O. Ospedale Papa Giovanni XXIII:
Hospitalized patients
Additional relevant MeSH terms:
Layout table for MeSH terms
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases